MAGIC‐DR : An interpretable machine‐learning guided approach for acute myeloid leukemia measurable residual disease analysis
Cytometry Part B: Clinical Cytometry · 2024-07 · 106 (4) · 239-251
DOI: 10.1002/cyto.b.22168 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cytometry Part B: Clinical Cytometry, online erschienen am 28.02.2024. Verfasst von Kevin Shopsowitz und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematopathology, Vancouver General Hospital, Vancouver, British Columbia, Canada. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Neoplasm, Residual, Flow Cytometry, Machine Learning. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: BD Bioscience Investigator Sponsored Study, Faculty of Medicine, University of British Columbia.
Abstract (Originalsprache)
Multiparameter flow cytometry is widely used for acute myeloid leukemia minimal residual disease testing (AML MRD) but is time consuming and demands substantial expertise. Machine learning offers potential advancements in accuracy and efficiency, but has yet to be widely adopted for this application. To explore this, we trained single cell XGBoost classifiers from 98 diagnostic AML cell populations and 30 MRD negative samples. Performance was assessed by cross‐validation. Predictions were integrated with UMAP as a heatmap parameter for an augmented/interactive AML MRD analysis framework, which was benchmarked against traditional MRD analysis for 25 test cases. The results showed that XGBoost achieved a median AUC of 0.97, effectively distinguishing diverse AML cell populations from normal cells. When integrated with UMAP, the classifiers highlighted MRD populations against the background of normal events. Our pipeline, MAGIC‐DR, incorporated classifier predictions and UMAP into flow cytometry standard (FCS) files. This enabled a human‐in‐the‐loop machine learning guided MRD workflow. Validation against conventional analysis for 25 MRD samples showed 100% concordance in myeloid blast detection, with MAGIC‐DR also identifying several immature monocytic populations not readily found by conventional analysis. In conclusion, Integrating a supervised classifier with unsupervised dimension reduction offers a robust method for AML MRD analysis that can be seamlessly integrated into conventional workflows. Our approach can support and augment human analysis by highlighting abnormal populations that can be gated on for quantification and further assessment. This has the potential to speed up MRD analysis, and potentially improve detection sensitivity for certain AML immunophenotypes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Hematopathology, Vancouver General Hospital, Vancouver, British Columbia, Canada.
- Department of pathology and laboratory medicine, University of British Columbia, Vancouver, British Columbia, Canada.
- Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
- Terry Fox Lab, BC Cancer, Vancouver, British Columbia, Canada.
Förderung
- BD Bioscience Investigator Sponsored Study
- Faculty of Medicine, University of British Columbia
Zitieren
APA
Shopsowitz, K., Lofroth, J., Chan, G., Kim, J., Rana, M., Brinkman, R., Weng, A., Medvedev, N., & Wang, X. (2024). MAGIC‐DR : An interpretable machine‐learning guided approach for acute myeloid leukemia measurable residual disease analysis. Cytometry Part B: Clinical Cytometry, 106(4), 239-251. https://doi.org/10.1002/cyto.b.22168
Vancouver
Shopsowitz K, Lofroth J, Chan G, Kim J, Rana M, Brinkman R, et al. MAGIC‐DR : An interpretable machine‐learning guided approach for acute myeloid leukemia measurable residual disease analysis. Cytometry Part B: Clinical Cytometry. 2024;106(4):239-251. doi:10.1002/cyto.b.22168
BibTeX
@article{Shopsowitz2024,
author = {Shopsowitz, Kevin and Lofroth, Jack and Chan, Geoffrey and Kim, Jubin and Rana, Makhan and Brinkman, Ryan and Weng, Andrew and Medvedev, Nadia and Wang, Xuehai},
title = {MAGIC‐DR : An interpretable machine‐learning guided approach for acute myeloid leukemia measurable residual disease analysis},
journal = {Cytometry Part B: Clinical Cytometry},
year = {2024},
volume = {106},
number = {4},
pages = {239--251},
doi = {10.1002/cyto.b.22168}
}
EUVIMED